Carnegie Investment Counsel’s Iovance Biotherapeutics IOVA Stock Holding History

Carnegie Investment Counsel’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$133K	Sell	32,000 -2,600	-8%	-$9.88K	﹤0.01%	543
2026 Q1	$121K	Sell	34,600 -1,400	-4%	-$4.48K	﹤0.01%	555
2025 Q4	$98.3K	Sell	36,000 -1,000	-3%	-$2.31K	﹤0.01%	559
2025 Q3	$80.3K	Buy	37,000 +6,000	+19%	+$14.2K	﹤0.01%	547
2025 Q2	$53.3K	Buy	+31,000	New	+$77.1K	﹤0.01%	538
2025 Q1	–	Sell	-27,000	Closed	-$200K	–	501
2024 Q4	$200K	Hold	27,000	–	–	0.01%	450
2024 Q3	$254K	Hold	27,000	–	–	0.01%	418
2024 Q2	$217K	Sell	27,000 -400	-1%	-$4.29K	0.01%	444
2024 Q1	$406K	Hold	27,400	–	–	0.01%	385
2023 Q4	$223K	Buy	27,400 +4,000	+17%	+$20.9K	0.01%	457
2023 Q3	$106K	Buy	23,400 +11,000	+89%	+$71.8K	﹤0.01%	477
2023 Q2	$87.3K	Buy	+12,400	New	+$88.8K	﹤0.01%	490
2021 Q4	–	Sell	-21,250	Closed	-$524K	–	507
2021 Q3	$524K	Sell	21,250 -3,000	-12%	-$70.7K	0.02%	317
2021 Q2	$631K	Buy	24,250 +200	+0.8%	+$5.2K	0.02%	297
2021 Q1	$761K	Sell	24,050 -2,000	-8%	-$82.9K	0.03%	272
2020 Q4	$1.21M	Buy	+26,050	New	+$1.03M	0.05%	218

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

MCP

Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Carnegie Investment Counsel's IOVA Position: Q2 2026 in Review

Carnegie Investment Counsel reduced its Iovance Biotherapeutics (IOVA) stake by 7.5% in Q2 2026, selling an estimated $9.88K and leaving 32,000 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #543.

Carnegie Investment Counsel first reported a position in IOVA in Q4 2020 and has held it in 16 quarters since. The position peaked at $1.21M in Q4 2020. 109 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Carnegie Investment Counsel held 32,000 shares of Iovance Biotherapeutics worth $133K as of Q2 2026.
Carnegie Investment Counsel sold 2,600 Iovance Biotherapeutics shares in Q2 2026, an estimated $9.88K.
Iovance Biotherapeutics made up ﹤0.01% of Carnegie Investment Counsel's portfolio in Q2 2026, its #543 holding.
Carnegie Investment Counsel first reported a position in Iovance Biotherapeutics in Q4 2020 and has held it in 16 quarters since.
Carnegie Investment Counsel's Iovance Biotherapeutics position peaked at $1.21M in Q4 2020.
109 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Carnegie Investment Counsel's 13F filing for Q2 2026, filed 30 Jul 2026.